Cambricon stock heads into Monday: what to watch after a Friday dip in China’s AI chip bellwether
25 January 2026
1 min read

Cambricon stock heads into Monday: what to watch after a Friday dip in China’s AI chip bellwether

Shanghai, Jan 26, 2026, 06:07 CST — Premarket

  • Cambricon’s Class A shares closed the session down 1.3%, at 1,334.99 yuan. 1
  • Traders are eyeing catalysts linked to the annual report timeline and the lock-up expiration this spring. 2
  • Broker targets followed by Futu point to an average price target that’s higher than the most recent close, highlighting just how mixed sentiment has grown after a choppy stretch. 3

Cambricon Technologies Corp. Ltd. Class A shares (688256.SS) dipped 1.33% in the previous session, closing at 1,334.99 yuan. They are set to open Monday’s trading in Shanghai at that level. 1

This matters because Cambricon has turned into a key stand-in for mainland China’s “homegrown AI chips” sector. Its moves often ripple through the STAR Market — Shanghai’s tech-focused board where it’s listed — pulling sentiment along. 4

As the market prepares to reopen, investors want more than just momentum. Their focus shifts to upcoming earnings reports and share-supply announcements rather than product news.

Cambricon has seen some volatility lately, slipping roughly 6% from last week according to TradingView’s data, though it still trades well above where it was a year ago. 5

Based in Beijing, the company develops AI chips for cloud servers, edge computing devices, and terminals, while also offering associated software solutions, Morningstar’s company profile shows. 6

Street expectations remain bullish. According to Futu’s broker data compiled and refreshed on Jan. 25, the average 12-month target price sits near 1,572 yuan, with forecasts spanning roughly 1,300 to 1,717 yuan. 3

Traders are zeroing in on timing and supply now. Eastmoney’s corporate calendar shows Cambricon’s full-year report set for March 13. It also highlights a lock-up expiry on April 16, releasing roughly 3.33 million previously restricted shares into the market. 2

The domestic AI-chip sector still tends to move as a group. A broad risk-off shift in China’s semiconductor space can drag Cambricon down fast, while a fresh boost in demand for onshore “AI infrastructure” stocks usually lifts the entire cluster.

Bulls face risks around valuation and expectations. According to Financial Times data, the stock trades roughly 16% under its 52-week peak and carries a triple-digit price-to-earnings ratio — meaning any slip in orders, margins, or guidance could hit hard. 7

Investors are eyeing the earnings report set for mid-March as the next major catalyst. According to Investing.com, the company is scheduled to release results on March 13. Traders see this date as a crucial test for the stock’s direction, whether it climbs higher or dips. 8

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
MediaTek stock hits limit-up: Nvidia-linked “N1” talk and Feb 4 results are the next tests
Previous Story

MediaTek stock hits limit-up: Nvidia-linked “N1” talk and Feb 4 results are the next tests

Qualcomm stock slips to $155.82 — why QCOM’s Feb. 4 earnings is the next big test
Next Story

Qualcomm stock slips to $155.82 — why QCOM’s Feb. 4 earnings is the next big test

Go toTop